Short Interest Coverage: What Next for DIADEXUS INCORPORATED (OTCMKTS:DDXSQ) Stock After Decrease in Shorted Shares?

December 1, 2016 - By Winifred Garcia   ·   0 Comments

Short Interest Coverage: What Next for DIADEXUS INCORPORATED (OTCMKTS:DDXSQ) Stock After Decrease in Shorted Shares?

The stock of DIADEXUS INCORPORATED (OTCMKTS:DDXSQ) registered a decrease of 11.11% in short interest. DDXSQ’s total short interest was 800 shares in December as published by FINRA. Its down 11.11% from 900 shares, reported previously. With 7,900 shares average volume, it will take short sellers 0 days to cover their DDXSQ’s short positions. The stock closed at $0.023 during the last session. It is down 98.77% since April 28, 2016 and is downtrending. It has underperformed by 104.69% the S&P500.

Diadexus, Inc. is a diagnostics company. The company has a market cap of $93,892. The Firm is engaged in developing and commercializing products that deliver healthcare providers with relevant information to assist in the management of their patients throughout the course of cardiac disease. It currently has negative earnings. The Company’s capabilities include manufacturing, assay development, Food and Drug Administration regulatory clearance, and marketing and selling products.

DDXSQ Company Profile

Diadexus, Inc., incorporated on November 27, 1995, is a diagnostics company. The Firm is engaged in developing and commercializing products that deliver healthcare providers with relevant information to assist in the management of their patients throughout the course of cardiac disease. The Company’s capabilities include manufacturing, assay development, Food and Drug Administration (FDA) regulatory clearance, and marketing and selling products. The Company’s commercially-available products consist of two FDA-cleared tests to measure Lp-PLA2: the PLAC Test ELISA Kit (the PLAC ELISA Test) and the PLAC Test for Lp-PLA2 Activity (the PLAC Activity Test). The Company’s other products include proADM; proET-1, which aids in predication of heart failure, and proANP, which aids in predication of heart failure. The Firm sells its diagnostic products to laboratories and promotes these products to the laboratories’ sales representatives, as well as directly to healthcare providers.

More notable recent diaDexus, Inc. (OTCMKTS:DDXSQ) news were published by: Marketwired.com which released: “Diadexus, Inc. and Sonic Healthcare USA Sign National Agreement for PLAC(R …” on May 23, 2016, also Marketwired.com with their article: “Diadexus, Inc. Names Jonathan Ruais as Vice President of Marketing” published on October 13, 2015, Seekingalpha.com published: “Return To Growth Could Send Diadexus Shares Higher (DDXS)” on December 25, 2014. More interesting news about diaDexus, Inc. (OTCMKTS:DDXSQ) were released by: Seekingalpha.com and their article: “DiaDexus Awaiting GSK’s Darapladib Pivotal Results” published on September 17, 2013 as well as Seekingalpha.com‘s news article titled: “DiaDexus: A Hearty Choice” with publication date: September 09, 2013.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Winifred Garcia


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>